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CObjectives: In some trials, particularly in oncology, patients whose
disease progresses under the comparator treatment are crossed over
into the experimental arm. This unplanned crossover can introduce
bias in analyses because patients who crossover likely have a different
prognosis than those who do not cross over; for instance, sicker pa-
tients not responding to standard therapy or those expected to benefit
the most may be selectively chosen to receive the experimental treat-
ment. Standard statistical methods cannot adequately correct for this
bias. We describe an approach designed to minimize the impact of
crossover, and illustrate this by using data from two randomized trials
inmultiplemyeloma (MM).Methods: TheMM-009/010 trials compared
lenalidomide and high-dose dexamethasone (LenDex) with dexa-
methasone alone (Dex). Nearly half (47%) of the patients randomized to
Dex crossed over to Len with or without Dex (Len/-Dex) at disease
progression or study unblinding. Data from these trials was used to
predict survival in an economic model evaluating the cost-effective-
ness of lenalidomide. To adjust for crossover, the prediction equations
were calibrated to match survival with Dex or Dex-equivalent thera-
pies in trials conducted by the Medical Research Council (MRC) in the O
orpo
al So
doi:10.1016/j.jval.2011.02.1182nited Kingdom. To adjust for differences between the MM and MRC
rial populations, a prediction equation was developed from the MRC
ata and used to predict survival by setting predictors to mean values
or patients in the MM-009/010 trials. The expected survival with Dex
ithout crossover was then predicted from the calibrated MM-009/010
quation (i.e., adjusted to match survival predicted from the MRC
quation). Results: The adjusted median overall survival predicted by
he MRC equation was 19.5 months (95%CI, 16.6–22.9) for patients with
ne prior therapy, and 11.6 months (95% CI, 9.5–14.2) for patients with
1 prior therapy. These estimates are considerably shorter than was
bserved in the clinical trials: 33.6 months (27.1-NE) and 27.3 months
95% CI, 23.3–33.3) as of December 2005. Conclusion: The calibration
ethod described here is simple to implement, provided that suitable
ata are available; it can be implementedwith other types of endpoints
n any therapeutic area.
eywords: bias, crossover, lenalidomide, multiple myeloma, survival,
nplanned.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Crossover from one clinical trial study arm to another can occur
because one arm is perceived to be better than another or in ther-
apeutic areas where patients’ condition can change suddenly and
require use of alternate therapy. This was noted in particular in
studies of surgical interventions, including coronary artery bypass
grafting (CABG) [1], where 38% of patients randomized to medical
therapy received CABG during the course of a study. Similarly,
patients randomized to undergo CABG sometimes refused surgery
and insteadwere treatedwithmedications [2]. This contaminationof
study arms leads tomixing of the effects and obscures the impact of
the intervention being studied; furthermore, it can introduce more
complex selection biases in the analyses of the study data because
* Address correspondence to: K. Jack Ishak, United BioSource C
E-mail: jack.ishak@unitedbiosource.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.crossover is inherently related to patients’ condition and prognosis
with the original treatment received.
Several approaches to handle crossovers have been considered,
including restricting analysis to patients who adhered to their as-
signed therapy, grouping patients based on treatment received, cen-
soring follow-up at crossover, transitioning patients to the group to
which they crossed over (by changing their treatment group indica-
tor when crossover occurs), and an intention-to-treat (ITT) analysis
that groupspatientsas randomized [3]. There isnoperfect solution to
dealing with crossovers, although an ITT analysis has been recom-
mended as the preferred approach, at least in cases where the num-
ber of crossovers is not excessive [4]. An ITT analysis preserves the
baseline comparability of groups given by randomization, albeit at
the cost of altering the interpretation of the estimated effect to en-
compass the potential impact of crossovers [3].
ration, 185 Dorval Avenue, Suite 500, Dorval, QC H9S 5J9 Canada.
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673V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 2 – 6 7 8Evenwhen crossovers arewell documented,methods based on
excluding patients, changing treatment group status, or censoring
data can induce serious bias. For instance, excluding patients
would likely introduce selection bias because these patients may
have a different prognosis than those who did not crossover. By
the same token, censoring could no longer be assumed to occur at
random, as it is linked to crossover. These biases not only affect
efficacy analyses, they also complicate the use of the trial data to
inform other aspects, such as meta-analysis [5] or health-eco-
omic assessments [6].
More complex statistical methods have been proposed to
eal with crossovers. Rank-preserving structural failure time
odels [7,8] and marginal structural models (or inverse proba-
ility weighting) [9] have been described as possible approaches
o dealing with non-random treatment assignment and non-
ompliance, of which crossover is a specific form. These meth-
ds use specialized estimation techniques to re-establish ran-
omization between treatment groups to derive an unbiased
reatment effect estimate. Whereas these methods rely entirely
n the data from the trial to correct the bias, we describe an
lternative method that uses external information to minimize
he impact of crossover in economic evaluations using predic-
ive equations for clinical endpoints. External data in this ap-
roach provides a reference value for endpoints in the absence
f crossover.
We describe and illustrate the method with an application in a
ooled analysis of two randomized, phase III clinical trials in pa-
ients who have received at least one prior therapy for multiple
yeloma (MM).
Methods
Case study
In two randomized clinical trials (MM-009/010) lenalidomide plus
high-dose dexamethasone was compared with dexamethasone
alone (Dex) in patients with MM who had failed at least one prior
therapy [10–12]. Data from these trials were used in an economic
evaluation of lenalidomide using a discrete event simulation
(which was part of a submission to National Institute for Health
and Clinical Excellence [NICE] in the United Kingdom). These anal-
yseswere based on time to progression (TTP) andpost-progression
survival (PPS), which, when combined, yielded the overall survival
(OS) for patients who progress.
The simulation used predictive equations for TTP and PPS de-
rived from the MM-009/010 trial data. The equations were ob-
tained via parametric survival analyses and included assigned
treatment, baseline characteristics, and best response achieved as
predictors.
In the trials, particularly at unblinding (which occurred at
disease progression in most cases), 47% of patients receiving
dexamethasone alone crossed over to the lenalidomide arm.
The crossover only occurred from the Dex arm. This high rate of
crossovers led to an overestimate of survival in the dexameth-
asone group because it mixes in the benefits of lenalidomide.
Thus, even if the prediction equations for TTP and PPS derived
from the trial fit the observed data very closely, they would not
reflect the true effect of adding lenalidomide to dexamethasone
compared with dexamethasone alone.
The aim was, therefore, to adjust for the impact of crossover
on the overall survival distribution predicted from the MM-009/
010 equations for patients receiving Dex to match an external
unbiased reference value (e.g., median survival time) – that is,
an estimated of the survival in a similar population where out-
comes are not affected by crossover. This is done by adding a
calibration term (i.e., a coefficient that modifies the intercept ofthe equation) to the MM-009/010 equations and estimating the
value that produces predictions that match a reference time
(e.g., median) reflecting survival in the absence of crossover.
This reference value was derived by analyzing data from four
trials conducted by the UK Medical Research Council (MRC) be-
tween 1980 and 2002 [13–17].1,2,3The MRC trials dataset com-
prised 2,942 patients starting treatment for MM with a median
follow-up of 5.7 years. First, an equation was developed for
overall survival as a function of predictors selected from various
patient characteristics. Second, this equation was used to esti-
mate the survival of the patients randomized to dexametha-
sone in the MM-009/010 trials by setting predictors in the MRC
equation to their corresponding values for Dex patients. The
estimated median survival was used as a reference value to
calibrate the MM-009/010 equations. A summary of the method
is illustrated in Figure 1.
Analysis of the MRC trials
Patients from the MRC trials were selected to match the lenalido-
mide trials’ inclusion criteria:
● All patients who received only first-line treatment in the MRC
trials were excluded because the lenalidomide trials required
prior failure of at least one treatment.
● All patients having failed an initial treatment and beginning
a second one were included as the “one-prior therapy” sub-
group.
● All patients having failed more than one treatment and begin-
ning a third- or fourth-line treatment were included as the
“multiple prior therapies” subgroup.
Variables reflecting patients’ characteristics were selected to
match those available from the MM-009/010 trials as closely as
possible. These included age, sex, Durie-Salmon disease stage,
presence of lytic bone lesions (at start of the first line of treatment),
performance status, maximum response, M-protein (g/L), and be-
ta-2 microglobulin levels (dichotomized at 2.5 mg/L), both at start
of first line, and at progressionwith each treatment. Best response
achieved was also considered.
Patients in theMRC trials received variousmedications, such
as melphalan (M7), melphalan and prednisone (MP), ABCM
(adriamycin, BCNU, cyclophosphamide, and melphalan), cyclo-
phosphamide, VAMP (vincristine, adriamycin, and methylpred-
nisolone), VAD (vincristine, adriamycin, and dexamethasone),
or HDP (dexamethasone and prednisone) among others. Ideally,
only data from patients receiving dexamethasonemonotherapy
would be included in the analyses, but this would have yielded
a relatively small sample. To fully leverage the data, all patients
were considered and a log-rank test was performed to assess
whether survival differed among regimens containing dexa-
MM-009/010
MRC OS Equation
TTP Equation
PPS Equation
Calibrated 
PPS Equation
Predicted 
median OS for 
MM-009/010
Predicted OS
Fig. 1 – Diagram of the process of crossover adjustment by
calibrating the PPS equation derived from the MM-009/010
trials using data from trials conducted by the MRC. MM,
multiple myeloma; MRC, UK Medical Research Council; OS,
overall survival; PPS, post-progression survival; TTP, time
to progression.methasone and those not using this drug. Calendar trends were
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674 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 2 – 6 7 8tested to ensure that survival from the older trials could be
pooled with the more recent studies and applied to the MM
trials. This was done by comparing overall survival by year of
enrollment starting from the first line of treatment received in
the MRC trials for all patients for whom survival data was avail-
able. Restricting this assessment to patients who fail first-line
treatment (i.e., the subset used in the main analyses) would be
subject to selection bias because starting second line treatment
in later years may be associated with better response to first line
treatment.
OS equations were derived from the MRC data separately for
one-prior and multiple-prior subgroups. Distributions com-
monly used to fit survival data (exponential, Weibull, log-nor-
mal, log logistic) were tested and the one that best fit the ob-
served data was selected. Best fit was assessed based on the
log-likelihood statistic and visual inspection of the observed
and predicted survival distribution with each of the functions.
Potential predictors were first identified by univariate equation
where each variable is included on its own. Significant predic-
tors were then included together into a multiple regression
equation. The final equation included only predictors that were
statistically significant (P  0.10) in the multiple regression
nalysis. For categorical variables, it is possible that the coeffi-
ients for some levels are statistically significant, even though
thers are not. In such cases, levels with non-significant coeffi-
ients were combined with adjacent levels. For example, in the
quation for the multiple prior group, Eastern Cooperative On-
ology Group (ECOG) levels 0 and 1 did not differ significantly,
nd were combined, so that the equation only has a coefficient
or 2–3 versus 0–1.The resulting equations were used to esti-
ate median OS times for the patients randomized to dexa-
ethasone in the MM-009/010 trials by setting the predictors to
he corresponding mean values (proportions for categorical
ariables) derived from the pooled MM-009/010. These median
imes were used as the reference values for calibration.
Calibration of MM-009/010 equations
Analyses of the MM-009/010 trials yielded three equations: two
for TTP (for one- and for multiple-prior therapies) and a third for
PPS. Separate PPS equations for patients with one and multiple
prior therapies were not derived due to limited number of
deaths. Instead, number of prior therapies (one vs. multiple)
was included as a predictor in the PPS equation. The two TTP
equations were based on a Weibull distribution and the PPS one
fit an exponential distribution. A Weibull regression model is
given by (Equation 1):
St;X expXt, (1)
here  is a scale parameter function that depends on a set of
predictors or patient characteristics (X) with corresponding re-
gression coefficients () (Equation 2):
X expX exp01X12X2 .. (2)
 is a shape parameter that does not depend on predictors. An
xponential distribution has the same formulation with shape
arameter fixed to 1 (i.e., St;X  exp  Xt) (based on the
parameterization used in the SAS software package [SAS Insti-
tute, Cary, NC]).
The PPS equation was considered to be most affected by cross-
overs because these occurred mostly at progression. Therefore, a
calibration term (denoted ) was added to adjust the PPS equation
o that the resulting median OS time (sum of TTP and PPS) was
qual to that derived from the MRC equation with patient charac-
eristics set to the mean values from the MM-009/010 trials. The
alibrated PPS equation based on anWeibull/exponential distribu-
ion has the following form:CX expX
 exp01X12X2 ... (3)
It follows then, that
CX
X

expX
expX
 exp,
rom which the following expression is obtained for :
InCX
X 	 (4)
The value of the calibration term was estimated by iterative
esting because it could not be calculated algebraically (since the
edians are not additive: that is, themedian of theOS distribution
btained by summing TTP and PPS is not the sum of the medians
f the TTP and PPS equations). The iterative estimation involved
he following steps:
. Determining the value  without calibration (i.e.,   0) by set-
ting the predictors in the PPS equation to their mean values for
patients randomized to dexamethasone:
X  exp01X 12X 2 ... (6)
2.
Set a tentative value for the calibration term by:
i. Setting a tentative median PPS time (tM) and calculating the
required value of  in the PPS equation using Equation 1:
M   In0.5⁄tM.
Table 1 – Baseline characteristics of patients in the MRC
trials.
Characteristic at start
of treatment (n [%],
unless otherwise
stated)
One prior group Multiple prior
group
Mean age (years) 64.7 65.1
Male 617 (56.6) 216 (57.6)
Performance status
(mapped to ECOG)*
0 231 (26.8) 47 (16.9)
1 329 (38.2) 91 (32.7)
2–3 302 (35.0) 140 (50.4)
Mean M-protein (g/L) 29.1 38.6
Beta-2 microglobulin 2.5
mg/L
859 (95.6) 293 (95.1)
Lytic bone lesions (at
first-line treatment)
709 (74.5) 246 (73.9)
Durie-Salmon stage (at
first-line treatment)
I 44 (4.0) 18 (4.8)
II 104 (9.5) 33 (8.8)
III 868 (79.6) 299 (79.7)
ECOG, Eastern Cooperative Oncology Group; MRC, UK Medical Re-
search Council.
* Performance status in the MM-009/010 trials wasmeasured using
the Eastern Cooperative Oncology Group (ECOG) scale. Because
theMRC trials used their own performance status scale, the levels
of the MRC performance status scale were mapped to the ECOG
scale: asymptomatic, ECOG 0; minimal symptoms, ECOG 1; re-stricted activity, ECOG 2–3; bedridden, ECOG 4.
4a
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equation 4 with M and as follows (Equation 4):
 InX 
M
	 (8)
3. Run the simulation model with the calibration term () added
to the PPS equation.
. Compare the predicted median OS with the reference median
derived from the MRC equations:
i. Stop if reference median value is reached.
ii. Otherwise return to step 2 and repeat steps with a new ten-
tative median PPS time.
This was done separately for the one- and multiple-prior ther-
py groups.
Results
MRC data were analyzed for the 1628 patients who achieved pla-
teau/stable disease from the total 2942 patients starting first-line
therapy. Of these, 1090 patients started second-line therapy and
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Fig. 2 – Observed OS among patients with one and multiple
prior therapies in the MRC trials. MRC, UK Medical
Research Council; OS, overall survival.
Table 2 – Prediction equation for OS in patients with one o
One
Coefficient es
Intercept 3.81 (0
Mean age (years) –0.023 (0
Performance status (mapped ECOG)
1 versus 0 –0.26 (0
2–3 versus 0 –0.56 (0
2–3 versus 0–1
Mean M-protein (g/L) 0.0049 (0
Beta-2 microglobulin 2.5 mg/L (yes versus no) 0.53 (0
Disease duration (years) 0.19 (0
Variable not included in the equation.
ECOG, Eastern Cooperative Oncology Group; MRC, UK Medical Research Cocomprised the one-prior therapy group. Data were available for
375 patients with multiple prior therapies; of these, 269 were
third-line treatment and 106 were fourth-line treatment. The
characteristics of these two groups are described in Table 1. Aver-
age follow-up was 24.4 months from start of second-line treat-
ment, during which 1015 of the 1090 second-line patients (93%)
died. The average follow-up in the multiple prior therapy group
was 14.2 months, and 354 of the 375 (94.4%) died. The survival
distributions in the two groups are shown in Figure 2. Themedian
overall survival (time to death)was 16.1 and 9.2months in the one-
and multiple-prior groups, respectively.
The best fitting distribution form for both one and multiple
prior therapy groups was an exponential function. Gender, Du-
rie-Salmon stage, and presence of lytic bone lesions were not
retained for second-line equation (P  0.10) (Table 2). The equa-
tion yields a median survival of 17.0 months for the MRC popu-
lation, compared with the observed 16.1 months (Fig. 3). The
prediction equation for the multiple prior therapy group is sum-
marized in Table 2. Age, gender, Durie-Salmon stage, M-protein
and presence of lytic bone lesions were not retained (P  0.10).
The equation also had very good fit to the data, as suggested by
predicted median OS of 9.4 months compared with 9.2 observed
(Fig. 4).
Applying the equations to patients randomized to dexa-
methasone in the lenalidomide trials (Table 3) yielded a median
of 19.5 months (95% CI, 16.6–22.9) for patients with one prior
therapy, and 11.6 months (95%CI, 9.5–14.2) for patients with
multiple prior treatments. These estimates were substantially
lower than observed in the MM-009/010 trials: 35.3 and 27.3
months, respectively [18] (based on the December 2005 cut of
the MM-009/010 data).
Dexamethasone was part of the second-line treatment regi-
men for 103 patients (9.5%) in the MRC trials. The regimen of pa-
tients not on dexamethasone consisted of M7/MP (24%), ABCM
(19%), cyclophosphamide (19%), VAMP or VAD (13%), or HDP (2%),
with the remainder on other treatments. Dexamethasone was
part of the treatment regimen for 59 (15.7%) patients in the multi-
ple prior groups. Survival for patients on regimens involving dexa-
methasone was compared with that of those not on dexametha-
sone-containing regimens. Survival did not differ significantly (P
0.88 for one-prior group, and P  0.13 for multiple prior group).
Differences in survival by year in which treatment was initi-
ated for patients entered into the MRC trials (Fig. 5) were not sta-
tistically significant (log-rank test, P 0.40). In fact, the ordering of
curves suggests poorer survival among patients starting treat-
ment after 1995.
ltiple prior therapies in the MRC trials.
r group Multiple prior group
te (SE) P value Coefficient estimate (SE) P value
0.0001 2.68 (0.35) 0.0001
0.0001 NA
0.008 NA
0.0001 NA
–0.26 (0.13) 0.044
0.008 NA
0.011 –0.49 (0.30) 0.101
0.0001 0.11 (0.03) 0.0001r mu
prio
tima
.35)
.005)
.10)
.10)
.002)
.21)
.02)uncil; NA, not applicable; OS, overall survival.
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Data from an external source (MRC multiple myeloma trials from
1980 to 2002) were used to adjust equations derived from two le-
nalidomide trials and to estimate OS with dexamethasone treat-
ment in the absence of crossover. The adjusted median survival
was 19.5 months for patients in the lenalidomide trials who had
failed one prior therapy, and 11.6 months for those with multiple
prior treatments, 42% and 59% lower (respectively) than what was
observed with crossover in the trials. This suggests crossover can
have a substantial impact on overall survival. This is consistent
with the large benefit observed for lenalidomide for TTP: 13.4 ver-
sus 4.6 months in MM-009/010 [18].
Beyond its use for calibration, the overall survival equation
derived from the MRC data may be used to predict survival for
myeloma patients starting treatment with standard therapies in
current day in other settings (e.g., for studies with short follow-
up). Our analyses did not reveal a difference in the survival of
patients receiving treatment regimens that included dexametha-
sone compared with those who did not receive this drug, and sur-
vival was similar over calendar time. These findings are in line
with a recent study based on data from the Mayo Clinic [19]. Al-
hough the authors noted a trend towards improved survival be-
ween 1995 and 2000, and a statistically significant improvement
rom 2000 and 2006, they attributed this to the use of high-dose
herapy (with stem-cell transplant) and novel therapies [19]. Thus,
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Fig. 3 – Observed and predicted OS for patients with one
prior therapy in the MRC trials. OS, overall survival.
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Fig 4 – Observed and predicted survival distributions for
patients with multiple prior therapies in the MRC trials.oth the MRC and Mayo Clinic data support the use of historical
ata as a robust indicator of the survival likely to be achieved
oday with traditional therapies for multiple myeloma.
The method described in this article adds to the body of ap-
roaches to deal with crossover in trials. Othermethods like rank-
reserving structural failure time models and marginal structural
odels use complex estimation procedures to derive unbiased
reatment effect estimates. Our approach usesmore standard sta-
istical methods but relies on external data expected to be free of
ias to calibrate equations derived from the trial data. Although a
eference value to calibrate may sometimes be found in the liter-
ture, this is prone to problems. Published studies may differ sub-
tantially from the trials from which the original trial equations
re derivedwith respect to design, methodology, and populations.
ttempts to correct for differences in populations based on aggre-
ate information (e.g., mean values of baseline characteristics)
ould be crude at best. The desired reference values may not be
eported exactly. Furthermore, if crossover is common in the ther-
peutic area, other studies may be prone to the same biases. For
nstance, crossovers were observed in another recent myeloma
tudy, the assessment of proteasome inhibition for extending re-
issions (APEX) trial, which compared bortezomib with dexa-
ethasone [20]. Analysis of patient-level data allows proper han-
ling of differences in populations and other aspects of study
esign (e.g., calendar period). Reference values can be derived
rom appropriate subsets that match the profiles of the original
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Fig. 5 – Overall survival distributions by calendar year of
enrollment into MRC trials. MRC, UK Medical Research
Table 3 – Characteristics of patients in the lenalidomide
trials (means and proportions) and predicted median OS
from MRC Equation.
One prior Multiple
prior
Mean age (years) 61.1 63.2
% ECOG 1 0.40 0.51
% ECOG 2,3 0.05 0.10
Mean M-protein (g/L) 23.8 27.9
Beta-2 microglobulin 2.5 mg/L 0.64 0.74
Disease duration (years) 3.2 4.9
Predicted median OS (months)
with 95% CI
19.5 (16.6–22.9) 11.6 (9.5–14.2)
ECOG, Eastern Cooperative Oncology Group; MRC, UK Medical Re-
search Council; OS, overall survival.Council.
677V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 2 – 6 7 8trial (if sample size permits). Otherwise, predictive equations
may be developed to predict unbiased reference values that are
adjusted to the characteristics of patients in the original clinical
trials.
The predictive equations for OS derived from the MRC data
source provided the reference values for calibration. It may be
asked why not use the MRC equation directly instead of going
through the calibration process to get unbiased survival estimates.
The primary reason to calibrate the original MM-009/010 equa-
tions is to preserve the shape of the distributions observed in these
studies. Although the parametric survival equations capture both
the shape and the scale of the distributions of the outcomes, only
the scale parameter is related to predictors of risk. At the same
time, the shape is assumed to be unique to the entire population
and may differ between the MM-009/010 trials and the MRC stud-
ies. Furthermore, the economic analyses where the MM-009/010
equations were used were structured to predict OS as the sum of
time to progression and post-progression survival (Fig. 1). Using
OS predictions directly from theMRC equationwould imply ignor-
ing the observed time to progression with dexamethasone in the
MM-009/010 trials, which were not affected by crossover.
With patient-level data from the MRC, it was possible to select
a population similar to the MM-009/010 trials, and to derive a pre-
diction equation to adjust for differences in patient characteris-
tics. Only fewpredictorswere available for consideration, and only
those that were available in theMM-009/010 trials could be used in
the MRC equations. Some variables had to be adapted to coincide
with the definitions in the MM-009/010 trials (e.g., performance
status). It needs to be acknowledged that there may be some un-
measured baseline characteristics associated with mortality that
differed between the MRC and MM-009/010 and, thus, could ac-
count for part of the observed differences in survival. Thus, it is
possible that part of the difference in the observed median sur-
vival and the one predicted from MRC is not completely attribut-
able to the crossover effect, but rather may be due to residual
differences in the populations not captured in the equations. This
may also occur if a predictorwas available in theMRC trials but not
in the MM-009/010, so that possible differences between the two
populations cannot be adjusted completely. No such variables
were identified, however, in this study; all variables with an a
priori clinical basis for being a predictor were available in both
sources. This may not always be the case, however. When the
predictors available in the two sources differ, it is important to
explore the potential influence of the non-common variables.
Another limitation is that only about 10% of patients used from
the MRC trials received regimens that included dexamethasone.
Mortality in these patientswas not distinguishable, however, from
that of patients who received regimens that did not include dexa-
methasone. Thus, using the combined population for these anal-
yses was justified.
The applications of themethod are broader than the case study
described in this article. For instance, the same technique can be
used to calibrate equations to predict outcomes for other medica-
tions and make external comparisons [21]. The calibration term
can be thought of as a measure of comparison, like a hazard ratio.
Furthermore, our case study was complicated by the use of TTP
and PPS equations to predict OS. The same approach could have
been used if OS had been modeled directly, in which case an alge-
braic solution would have been possible to derive the value of the
calibration term. Finally, the technique is not only applicable to
survival equations. The same strategy can be applied to adjust
other types of equations, like those derived from logistic or linear
regressions.
A key question is whether calibration should be based on the
mean rather than the median (or other percentiles). The mean is
certainly more appropriate for outcomes analyzed with linear or
logistic regression models, as these are inherently based on mod-eling the means of the underlying distributions. For time to event
outcomes, however, we believe the median, or percentiles of the
distributions are more appropriate measures. Using the mean for
these outcomes poses two possible problems. Event times tend to
have a skewed distribution with a long tail that can greatly influ-
ence the mean. Furthermore, the tail of the distribution is usually
not observed (follow-up is limited in studies); thus, the tails of
predicted distributions are not always directly supported by data
but rather projected based on the pattern of the earlier portions of
the distribution where the observed data lie. As a result, the pre-
dicted means are more susceptible to be affected by errors in pre-
diction. Predicted percentiles such as themedian are less prone to
these types of problems because they are not affected by the tail of
the distribution and can be chosen to liewithin the observed range
of the data or at least very close to this. Therefore, we recommend
using centiles for calibration with time-to-event equations, al-
thoughwe realize that theremay be diverging views. For instance,
inNICE’s appraisal of the lenalidomide submission [22], the review
committee noted that the choice of calibration at themean versus
median was a matter of scientific judgment, but ultimately fa-
vored use of the mean. This was justified by the fact that incre-
mental cost-effectiveness ratios are based on means. Further-
more, they argued that because the overall survival distribution
was observed nearly completely in the MRC data, the mean could
be estimated accurately.We chose to calibrate OS at themedian as
this represents the middle of the survival distribution. Other fac-
tors should be taken into account in deciding a point for calibra-
tion. For instance, if a comparison of the reference and original
trial survival curves reveal an early deviation, a point in the earlier
part of the curvemay bemore appropriate. Furthermore, although
the distributions in our example were exponential, only the scale
parameter needed to be manipulated. More complex forms, like
Weibull or Gompertz, involve both a scale and shape parameter.
Although usually only the scale parameter is related to predictors
(via regression) one may consider calibrating by changing the
shape parameter depending on what aspect of the distribution is
thought to be most affected by crossover.
Conclusions
The calibration method described in this article adds to the exist-
ing set of methods to deal with crossover in trials. The approach is
relatively simple to implement and readily extendable to any type
of statisticalmodels (other than survival regressions). Though ide-
ally implemented with patient level data, it may also be used with
published information. Its application to the MM-009/010 trials
suggests that crossover had a substantial impact on survival esti-
mates.
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